INCY

INCY

USD

Incyte Corp. Common Stock

$102.920+1.560 (1.539%)

वास्तविक समय मूल्य

Healthcare
जैव प्रौद्योगिकी
संयुक्त राज्य अमेरिका

मूल्य चार्ट

Loading Chart...

मुख्य मीट्रिक्स

बाजार मीट्रिक्स
कंपनी के मौलिक सिद्धांत
ट्रेडिंग आँकड़े

बाजार मीट्रिक्स

खुलना

$101.360

उच्च

$103.860

कम

$100.020

मात्रा

2.74M

कंपनी के मौलिक सिद्धांत

बाजार पूंजीकरण

20.2B

उद्योग

जैव प्रौद्योगिकी

देश

United States

ट्रेडिंग आँकड़े

औसत मात्रा

2.00M

एक्सचेंज

NMS

मुद्रा

USD

52-सप्ताह रेंज

कम $53.56वर्तमान $102.920उच्च $103.86

संबंधित समाचार

Analyst Upgrades

Piper Sandler Maintains Overweight on Incyte, Raises Price Target to $102

Piper Sandler analyst Allison Bratzel maintains Incyte with a Overweight and raises the price target from $82 to $102.

और देखें
Piper Sandler Maintains Overweight on Incyte, Raises Price Target to $102
GlobeNewswire

Prelude Therapeutics Announces Exclusive Option Agreement with Incyte to Advance Mutant Selective JAK2V617F JH2 Inhibitors

Incyte secures an exclusive option to acquire Prelude's mutant selective JAK2V617F JH2 inhibitor program Mutant selective JAK2V617F JH2 inhibitors have disease-modifying potential in treating patients living with

और देखें
Prelude Therapeutics Announces Exclusive Option Agreement with Incyte to Advance Mutant Selective JAK2V617F JH2 Inhibitors
Analyst Upgrades

Guggenheim Upgrades Incyte to Buy, Announces $125 Price Target

Guggenheim analyst Michael Schmidt upgrades Incyte from Neutral to Buy and announces $125 price target.

और देखें
Guggenheim Upgrades Incyte to Buy, Announces $125 Price Target
BusinessWire

Incyte Announces More than 50 Abstracts Accepted for Presentation at the 2025 ASH Annual Meeting

INCA033989, a first-in-class mutant calreticulin (mutCALR)-targeted monoclonal antibody, will be showcased in three presentations, including new Phase 1 monotherapy and combination data in myelofibrosis (MF), updated

और देखें
Incyte Announces More than 50 Abstracts Accepted for Presentation at the 2025 ASH Annual Meeting
BusinessWire

Incyte to Present at Upcoming Investor Conferences

Incyte (NASDAQ:INCY) announced today that it will present at the following investor conferences during the month of November: Guggenheim Annual Healthcare Innovation Conference on Monday, November 10, 2025 at 10:00

और देखें
Incyte to Present at Upcoming Investor Conferences
GlobeNewswire

Knight Therapeutics Announces Approval and Launch of MINJUVI® (tafasitamab) in Argentina

MONTREAL, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX:GUD) ("Knight") a pan-American (ex-USA) specialty pharmaceutical company, announced today that its Argentine affiliate, Laboratorio LKM

Analyst Upgrades

RBC Capital Maintains Sector Perform on Incyte, Raises Price Target to $84

RBC Capital analyst Brian Abrahams maintains Incyte with a Sector Perform and raises the price target from $81 to $84.

अपडेट रहें

मूल्य अलर्ट सेट करें, AI विश्लेषण अपडेट और वास्तविक समय बाजार समाचार प्राप्त करें।